Quva Pharma Moves CAPS Medications to New Jersey
Quva Pharma is transferring compounded drugs acquired from Central Admixture Pharmacy Services into its Greenwich Township facility.
Updated on Nov. 13, 2026 in Healthcare

Quva Pharma, headquartered in Sugar Land, Texas, announced in September that it acquired a range of medications from Central Admixture Pharmacy Services, a B. Braun subsidiary that has exited the 503B compounding business. The transfer of those products into Quva's Greenwich Township, New Jersey facility is underway.
Why it matters
The FDA relaxed compounding rules in early September after identifying a potential hospital supply gap for parenteral nutrition products caused by the closure of the CAPS facilities. The move is intended to help keep sterile drugs flowing to healthcare facilities in the state and beyond.
Quva has recruited 36 staff from the CAPS business and is focusing first on six neonatal starter TPN formulations, four cardioplegia preparations, and two Heparin products, compared with CAPS's prior network of two 503B pharmacies. The extraction does not specify when the full transfer will be complete.
The players
Quva Pharma
Quva Pharma is a Sugar Land, Texas-based compounding company operating 503B sterile drug manufacturing facilities in Texas and Greenwich Township, New Jersey.
B. Braun
B. Braun is a medical device and pharmaceutical company whose subsidiary Central Admixture Pharmacy Services exited the 503B compounding business.
Central Admixture Pharmacy Services
Central Admixture Pharmacy Services is a B. Braun subsidiary that operated 503B compounding pharmacies in Phoenix, Arizona, and Upper Macungie Township, Lehigh County.
U.S. Food and Drug Administration
The FDA is the federal agency that regulates drug compounding and relaxed the rules for neonatal starter parenteral nutrition products in early September.
The details
The transfer is a complex process supported by both B. Braun/CAPS and the FDA, and Quva's 503B facilities produce large batches of sterile drugs for sale to healthcare facilities. Quva also plans to undertake manufacturing, warehousing, and distribution operations in Allentown, where early discussions with property owners are underway.
Timeline
September: Quva announced its acquisition of the CAPS medication portfolio.
Early September: The FDA relaxed compounding rules for neonatal starter parenteral nutrition products.
Early 2027: Quva expects the first supply of compounded medications to reach hospitals.
Market Landscape
The FDA's early-September relaxation of compounding rules for neonatal starter parenteral nutrition products was issued to close a hospital supply gap created when CAPS exited the 503B business. Quva's acquisition and relocation of those medications is the industry response that follows that regulatory action, as compounders absorb the portfolio of an exiting competitor.
For hospitals that depend on neonatal parenteral nutrition, cardioplegia, and Heparin products, the transfer aims to preserve supply continuity after CAPS exited the business. New Jersey healthcare providers should watch for when these specific formulations become available through Quva's Greenwich Township facility.
The takeaway
The CAPS exit shows how quickly specialized sterile drug supply can narrow, and how regulators and rival compounders work to fill the gap. Healthcare providers should monitor timelines for the first deliveries before relying on new supply sources.
What happens next
Quva Pharma expects the first supply of compounded medications to reach hospitals in early 2027, which will be the first measurable test of the transfer.
Further reading
For related coverage, explore more Healthcare news from across the industry.
Source note: This article includes information reported by WFMZ.






